| http://www.w3.org/ns/prov#value | - no difference in overall survival and therefore this combination strategy is unlikely to be developed further.Unlike bevacizumab, VEGF tyrosine kinase inhibitors have demonstrated objective response rates of approximately 10% when given as monotherapy.161, 162 However, additional toxicities such as diarrhea, mucositis, hand-foot syndrome, and fatigue are noted with many of these agents.
|
